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Background: The aim of the study was to determine the most common treatment strategies and their costs for
patients with an inadequate response to first-line antidepressant treatment (AD) in primary care.
Method: A retrospective cohort study of medical records from six primary care centers was conducted. Adults with
a major depressive disorder diagnosis, at least 8 weeks of AD treatment after the first prescription, and patient
monitoring for 12 months were analyzed. Healthcare (direct cost) and non-healthcare costs (indirect costs; work
productivity losses) were described.
Results: A total of 2,260 patients were studied. Forty-three percent of patients (N = 965) presented an inadequate
response to treatment. Summarizing the different treatment approaches: 43.2% were switched to another AD,
15.5% were given an additional AD, AD dose was increased in 14.6%, and 26.7% remained with the same
antidepressant agent. Healthcare/annual costs were 451.2 Euros for patients in remission vs. 826.1 Euros in those
with inadequate response, and productivity losses were 991.4 versus 1,842.0 Euros, respectively (p < 0.001).
Conclusion: Antidepressant switch was the most common therapeutic approach performed by general
practitioners in naturalistic practice. A delay in treatment change when no remission occurs and a significant
heterogeneity in management of these patients were also found.
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Major depressive disorder (MDD) is one of the most
common mental diseases in the general population, with
an estimated annual prevalence of 5.7% [1]. MDD is a
disabling disease that impairs health-related quality of
life and causes an increase in healthcare resource
utilization [2-6]. Some studies show that one third of
costs are derived from healthcare and the highest are in-
direct costs associated to loss of work productivity
[3,5,6].
It is usually recommended that patients with MDD are
initially treated in primary care (PC) and approximately* Correspondence: jorgealejandro.maurino@astrazeneca.com
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distribution, and reproduction in any medium80% of them are managed in PC only [7-10]. There is
limited information on the referral rates to mental
health care and referral criteria. In a study conducted in
Spain, 23% of general practitioners (GPs) referred
patients with major depression to the psychiatrist [11].
In a survey conducted by Villava and Caballero (2006)
among more than 1,000 GPs in Spain, the mean referral
rate was 24%, being higher in physicians who reported
poorer training and greater demand for care [12]. As
regards referral criteria, the main reasons reported were
severity of the episode (87%), lack of response to treat-
ment (41%), and express request by the patient (37%).
Regardless of which antidepressant (AD) is chosen, the
final aim of therapy for MDD is to achieve a total remis-
sion of symptoms. Lack of remission has been associated
with a higher risk of recurrences, more chronicentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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sodes, and a worse functioning [8,13-16]. Only few stud-
ies have directly measured the financial impact of MDD,
showing that costs are significantly lower when patients
achieved remission of symptoms [3,5].
The introduction of newer-generation antidepressants
has improved our ability to treat depression, although
only 35-40% of patients will experience a remission of
symptoms during an initial 8-week trial [17-19]. Four
different pharmacologic approaches are available for
treating patients who have experienced inadequate re-
sponse to a first-line antidepressant: increasing the dose
of the antidepressant, switching to a different anti-
depressant, combining the initial antidepressant with a
second one, and augmenting the treatment with a non-
antidepressant agent [20]. Definition of inadequate re-
sponse is still controversial, but most experts define it as
failure to achieve symptomatic remission [13,21,22].
The question of how to proceed with the next step in
MDD treatment after an initially unsuccessful trial is
crucial due to the diversity of therapeutic approaches
available. The aim of the study was to determine the
most common treatment strategies and their costs for
patients with an inadequate response to first-line anti-
depressant in primary care.
Methods
Study design and data extraction
We carried out an observational, retrospective cohort
study of medical records held by the health care pro-
vider, Badalona Serveis Assistencials (BSA). The study
population consisted of patients from six primary health
care centres managed by BSA. They cover a population
of 120,000 inhabitants, mostly urban, middle-low socio-
economic status, and with a predominance of industrial
workers.
Personal identification of patients was removed from
the start, subsequently maintaining complete dissoci-
ation between patient identification and their clinical
data, as requested by Spanish legislation protecting con-
fidentiality of patient health data. Then, written consent
was not required for this type of study. The study proto-
col was approved by the investigational review board of
the Hospital Germans Trias i Pujol (Badalona, Spain;
NCT01446692).
Patients
All patients who met the following characteristics were
included in the study: (a) aged over 18; (b) a diagnosis of
major depressive disorder according to the International
Classification of Primary Care (ICPC-2, code P76), either
as a single (incidence) or recurrent episode (prevalence,
new episode) [23]; (c) antidepressant treatment started be-
tween January 1st, 2008 and December 31st, 2009; (d)prescription meeting the criteria for a minimum adequate
treatment (at least 8 weeks of AD treatment since the first
prescription); (e) inclusion in the long-term prescriptions
program; (f) who had not received any antidepressant
treatment within the previous 6 months; and (g) a patient
follow-up during a subsequent initiation of treatment.
Study groups and remission criteria
Patients were divided into two study groups: a) patients
with an inadequate response to first-line AD treatment
(no remission), and b) patients in remission after the
first AD treatment. Patients were followed up for the
main outcome measures of the study at 6 and 12 months
from the date of start of treatment. Patients were consid-
ered to be in remission when they had a Hamilton De-
pression Rating Scale (HDRS) total score ≤ 7 points after
at least 8 weeks of AD treatment in adequate doses
[24,25]. Most patients completed the scale. However, the
decision to change the intervention strategy was always
at the physician´s discretion. The HDRS is routinely per-
formed among patients with depressive symptoms in our
centers by GPs or nurses.
The following options were considered as potential
strategies for a change of drug treatment: increasing the
dose of AD, change to a different AD, combination with
a second AD, or association with a new drug without in-
trinsic antidepressant properties (augmentation) [20].
Sociodemographic variables and comorbidity
The main study variables were: age (continuous and by
ranges) and sex, as well as personal history taken from the
International Classification of Primary Care (ICPC-2) [23].
The following were used as summary variable for overall
comorbidity for each patient seen: a) the Charlson Comor-
bidity Index as an approximation to patient severity [26]
and b) the Case-mix Index, obtained from the Adjusted
Clinical Groups (ACG), a system classifying patients by
iso-resource consumption [27]. The algorithm of the
Grouper ACGW Case-mix System consists of a number of
consecutive steps until the 106 mutually exclusive ACG
groups are obtained, one for each patient seen. The
ACG application provides resource utilization bands
(RUBs), so that each patient is grouped into one of the
five mutually exclusive categories based on overall mor-
bidity (1: healthy or with a very low morbidity, 2: low
morbidity, 3: moderate morbidity, 4: high morbidity, and
5: very high morbidity).
Drugs prescribed, treatment compliance and persistence,
and referrals
Prescriptions of the following therapeutic classes and
active ingredients for the central nervous system or psy-
choactive drugs were considered: ADs (N6A), antipsycho-
tics and mood stabilizers (N5A), anxiolytic drugs (N5B),
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[28]. Compliance was defined as the extent of agreement
of patient behavior with use of medication based on
recommendations by healthcare professionals in charge of
the patient. Compliance was estimated as the ratio be-
tween the total number of tablets dispensed and the total
number of tablets recommended or prescribed, assuming
that drug dispensing (purchase of medication at the phar-
macy) does not represent actual consumption or intake,
but is closely associated with this [29]. Treatment persist-
ence was defined as the time in weeks without discontinu-
ation of initial treatment or without switching to another
medication at least 8 weeks after initial prescription. The
number of and reasons for referrals to mental health care
were analyzed.Health and non-health care resources and cost estimation
Direct healthcare costs (direct costs) were those related
to care activity (medical visits, diagnostic or therapeutic
requests, etc.) performed by professionals, while non-
healthcare or indirect costs were those related to work
productivity losses. The productivity losses were calcu-
lated in terms of days off work [30]. The design of the
cost system was defined taking into account the char-
acteristics of the organization and the degree of devel-
opment of the available information systems. The
analytic unit serving as the basis for final calculation
(during the study period) was the patient seen, and
cost was expressed as mean cost per patient (cost/unit).
The different study concepts and their economic as-
sessment are detailed in Table 1 (year 2009). The dif-
ferent rates were obtained from analytical accounting
of the centers, except for medication and days of sick
leave. Prescriptions (acute, chronic, or demand medical
prescriptions) were quantified based on the retail price
by pack at the time of prescription. Days of disability
for work were considered as non-healthcare costs (in-
direct costs). The cost was quantified based on theTable 1 Details of unit costs of healthcare resources and
work productivity losses
Healthcare and non-healthcare resources Unit cost 2009 (Euros)





Drug prescription Retail price/pack
Work productivity-Indirect Costs
Labor cost per day of sick leave* 79.61
Source of healthcare resources: own analytical accounting. *Source: INE-
National Institute of Statistics [31].interprofessional minimum wage (source: Spanish Insti-
tute of Statistics- INE) [31].Statistical analysis
A univariate descriptive statistical analysis was performed
using the mean, standard deviation, and 95% confidence
intervals (CI). Normal data distribution was confirmed
using a Kolmogorov-Smirnov test. A nonparametric
Kaplan-Meier survival analysis was used to test treatment
persistence (median time). ANOVA, Chi-square, and lin-
ear Pearson’s correlation tests were used for bivariate ana-
lysis. To assess the association of related factors (variables)
for each specific strategy, a multinomial logistic regression
analysis was performed (procedure: main components).
Cost comparison was performed in accordance to recom-
mendations by Thompson and Barber, specifically on the
comparison of average health care cost between the study
groups [32]. For correction of the cost model was used
the analysis of covariance (ANCOVA), with sex, age,
comorbidity, and Charlson index as covariates (procedure:
estimation of marginal means; Bonferroni correction).
SPSSWIN version 17 software was used, and values of
p < 0.05 were considered statistically significant.Results
The number of patients >18 years screened was 83,370,
of whom 72,372 (86.8%) requested care. Finally, 2,260
subjects who met the inclusion criteria were analyzed
(Figure 1). Mean age was 58.8 years (74% females),
RUBs were 2.5 points, and mean number of comorbid-
ities was 4.6 per patient. Dyslipidemia (43.6%), high
blood pressure (34.2%), and fibromyalgia (25.2%) were
the most common comorbidities. Annual incidence
(new cases) was 16.3% (95% CI: 14.5-17.5%), with a cu-
mulative incidence rate of 6.8/1,000 inhabitants/year
(95% CI: 6.1-7.9/1,000 inhabitants/year).
Forty-three percent of patients (N= 965; 95% CI:
40.0%-46.4%) presented an inadequate response to first-
line AD treatment (during patients´ follow-up period:
1 year). Patients without remission were older (61.0 vs.
57.1 years; p < 0.001), females (76.8% versus 71.9%;
p = 0,009), and retired (63.1% vs. 47.0%; p < 0.001). These
patients had higher mean values of general morbidity
(5.3 vs. 4.1 episodes/year) and RUB/year (2.7 versus 2.4)
(Table 2).
Summarizing the distribution of different treatment
approaches for the management of inadequate AD initial
response in naturalistic practice: 43.2% were switched to
another AD (time elapsed: 6.5 months), 15.5% were
given an additional AD (time elapsed: 5.4 months), AD
dose was increased in 14.6% (time elapsed: 6.1 months),
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Figure 1 General study disposition. Years 2008–2009.
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percentages of treatment compliance (65.1% versus 67.7%;
p < 0.001) and treatment persistence at 12 months (31.8%
[95% CI: 27.5%-35.9% versus 53.2% [95% CI: 50.5%-
56.9%]; p < 0.001). An acceptable correlation was found
between treatment compliance and persistence (r = 0.692;
p < 0.001). Referral rate to mental health care was 18.8%
(95% CI: 17.2%-20.4%). The reasons were: inadequate re-
sponse to treatment (47.5%), disease severity (42.1%) and
patient´s decision (10.4%). In patients with remission, re-
ferral rate was lower (16.8% versus 21.6%; p < 0.001) and
time from start of treatment to referral was shorter (3.4
versus 6.4 months; p < 0.001), Figure 2. Table 4 shows the
relationship between treatment compliance and persist-
ence, as well as referrals to psychiatry care.
Table 5 shows resource utilization and cost estimation
(mean/unit/year) according to AD response. Patients
with an inadequate AD response presented higher mean
number of visits/year (16.8 vs 11.1; p < 0.001) and days
of work disability (20.2 versus 12.8 days; p < 0.001) com-
pared with patients achieving remission. Total annual
gross cost of patients demanding care during the
12 months of follow-up amounted to 4.3 million Euros.
Healthcare (direct) costs and costs derived from work
productivity losses (non-healthcare, indirect costs) repre-
sented 32.7% and 67.3% of total costs, respectively
(p < 0.001). Medical visits accounted for 16.3%, drugs
prescribed for 15.6%, and diagnostic tests for 0.8%. Mean
cost per patient of gross direct costs by remission status
(absence/presence) was 857.2 versus 443.2 Euros,
p < 0,001. In the adjusted model, total costs were 2,668.1
Euros (95%CI: 2,346.9-2,989.2) versus 1,442.6 Euros
(95%CI: 1,180.9-1,704.2), respectively; p < 0.001. Costs
from work productivity losses were 1,842.0 versus 991.4Euros, and healthcare (direct) costs were 826.1 versus
451.2 Euros, respectively; p < 0.001. These differences
persisted in all cost components (gross and adjusted).
In general, patients undergoing no change in AD were
incident cases (29.2%), with low treatment compliance
(62.3%) and referral rate (17.1%). Patients under a change
to a new AD were prevalent cases (81.5%) with longer dis-
ease duration (5.2 years) and referred to psychiatry care
due to a lack of response to treatment (53.1%). Patients re-
ceiving AD combination had a similar profile. Most of
them (90.1%) were prevalent cases with long disease dur-
ation (6.4 years). However, they showed a greater referral
rate (28.2%), mainly due to disease severity (53.3%), and
also have a higher mean healthcare cost (1,041.8 Euros).
Patients in whom AD dose was increased were younger
(52.9 years) and new cases (20.4%), with high treatment
compliance (69.2%).
In the logistic regression model, predictors associated
with lack of remission included: treatment non-
compliance (OR= 1.7; 95%CI: 1.3-2.7), referral to a
psychiatrist (OR= 1.5; 95%CI: 1.3-1.8), years from dis-
ease onset (OR= 1.2; 95%CI: 1.1-1.3), age (OR= 1.1; 95%
CI: 1.0-1.3), and presence of comorbidity (OR= 1.1; 95%
CI: 1.0-1.2); p < 0.05. No variable was associated with a
greater probability to the type of strategy used.
Discussion
In our study, 42.7% of patients presented an inadequate
response to first-line antidepressant treatment. AD
switch was the most common therapeutic approach
(43.2%) performed by GPs after the lack of remission in
daily clinical practice. Time until the change of strategy
was extremely long (mean 6.5 months) and 26.7% of
patients remained with the same initial AD.
Table 2 Sociodemographic and clinical characteristics
Groups Inadequate response Remission Total P value
Number of patients, % N=965 (42.7%) N=1,295 (57.3%) N=2,260
Mean age, years 61.0 (15.1) 57.1 (16.4) 58.8 (15.9) <0.001
Ranges: 18–44 years 13.7% 24.6% 19.9% <0.001
45–64 years 46.1% 42.6% 44.1% <0.001
65–74 years 18.1% 13.8% 15.7% <0.001
> 74 years 22.1% 19.0% 20.3% <0.001
Gender, female 76.8% 71.9% 74.0% 0.009
Occupational status, retired 63.1% 47.0% 53.9% <0.001
Mean number of comorbidities 5.3 (3.5) 4.1 (3.3) 4.6 (3.4) <0.001
Mean RUBs 2.7 (0.9) 2.4 (1.1) 2.5 (1.1) <0.001
RUB-1 17.1% 23.4% 20.7% <0.001
RUB-2 9.3% 18.4% 14.5% <0.001
RUB-3 59.5% 49.5% 53.8% <0.001
RUB-4 12.3% 7.1% 9.3% <0.001
RUB-5 1.8% 1.5% 1.6% <0,001
Mean Charlson index 0.4 (0.7) 0.3 (0.8) 0.4 (0.7) NS
Associated comorbidities
Arterial hypertension 39.0% 30.6% 34.2% <0.001
Diabetes mellitus 17.1% 12.9% 14.7% 0.005
Dyslipidemia 49.7% 39.1% 43.6% <0.001
Obesity 22.3% 18.7% 20.2% 0.035
Active smoking 22.9% 25.9% 24.6% NS
Alcoholism 4.2% 4.4% 4.3% NS
Ischemic heart disease 7.0% 3.7% 5.1% <0.001
Cerebrovascular events 10.6% 7.7% 8.9% 0.019
Cardiovascular events 15.4% 10.4% 12.6% <0.001
Organ insufficiency 11.5% 11.1% 11.3% NS
Bronchial asthma. 8.8% 5.6% 7.0% <0.001
COPD 4.2% 3.2% 3.6% NS
Neuropathies 2.4% 1.5% 1.9% NS
Dementia (all types) 4.9% 3.2% 3.9% 0.032
Organic psychosis 3.5% 2.9% 3.1% NS
Malignant tumors 10.3% 7.1% 8.5% 0.008
Fibromyalgia 28.9% 22.4% 25.2% <0.001
Time since MDD onset, years 4.8 (3.8) 3.5 (3.6) 4.1 (3.7) <0.001
New, incident cases (N= 738) 23.3% 38.7% 32.2% <0.001
Prevalent cases (N= 1,522) 76.7% 61.3% 67.8% <0.001
RUBs: resource utilization bands (morbidity burden of patients); COPD: chronic obstructive pulmonary disease; MDD: major depressive disorder; values are given
as percentage or mean (standard deviation); NS: not significant.
Patients were considered to be in remission when they had a Hamilton Depression Rating Scale total score ≤ 7 points after at least 8 weeks of AD treatment in
adequate doses [24,25].
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among patients with MDD showed that compliance was
low, ranging from 25% to 50% [33-35]. In our study,
patients achieving remission showed better rates of com-
pliance (67.7% vs. 65.1%) and treatment persistence(53.2% vs. 31.8%), respectively. Our results are clearly
higher, possibly because of the indirect measurement
method used [36]. Establishing and maintaining a sup-
porting therapeutic relationship is crucial for ensuring
compliance and symptom remission. Factors associated
Table 3 Pharmacologic strategies
Groups Same AD1 AD change2 Combination3 Dose increase4
Number of patients, % N=451 (26.7%) N=417 (43.2%) N=53 (15.5%) N=44 (14.6%)
Time to change, months
Mean — 6.5 (3.9) 5.4 (1.9) 6.1 (3.5)
Median — 5.7 4.0 5.2
Mean age, years 61.9 (15.1) 60.8 (15.0){ 61.1 (15.4) 52.9 (11.4),
Gender, female 75.4% 77.2% 83.1% 79.5%
Comorbidity
Mean number of episodes 5.1 (3.4) 5.5 (3.4) 5.8 (3.9) 5.1 (3.6)
Mean RUBs 2.7 (0.9) 2.7 (0.9) 2.8 (1.0) 2.5 (1.0)
Mean Charlson index 0.4 (0.7) 0.5 (0.7) 0.4 (0.6) 0.3 (0.7)
Duration of MDD, years 4.1 (3.7) 5.2 (3.5){ 6.4 (5.2) 5.1 (3.5)
Incident cases (N= 222) 29.2%, 18.2% 9.8% 20.4%{
Prevalent cases (N= 743) 70.1% 81.5%{ 90.1%, 79.5%
Treatment compliance 62.3%, 67.1% 64.8% 69.2%,
Treatment persistence 30.5%, 33.1% 34.8% 43.2%,
Referrals to psychiatry (N = 199)
Referral rate 17.1%{ 23.5% 28.2%{ 20.5%
Mean referrals per patient 0.2 (0.4) 0.2 (0.5) 0.3 (0.5){ 0.2 (0.5)
Time to referral, months 6.3 (4.1) 6.8 (4.0) 4.4 (3.3) 6.2 (3.8)
Reasons for referral
Disease severity (N = 82) 39.0% 39.8% 53.3%{ 55.6%,
No response to treatment (N= 107) 59.7%, 53.1%{ 33.3% 44.4%
Patient decision (N= 10) 1.3% 7.1% 13.3% 0.8%
Cost model (euro)
Healthcare costs 782.1 901.4 1,041.8 984.9
Non-healthcare costs (productivity) 1,392.4 1,710.6 1,631.3 1,978.1
Total costs 2,174.4 2,612.0 2,673.1 2,963.1
RUBs: resource utilization bands; values given as percentage or mean (standard deviation); statistical significance: {p< 0.05 for comparisons between each type of
strategy versus the total group with no remission (significance tests: Chi-square and ANOVA; use of post hoc tests). N = 965.
1 Same treatment: no changes made in 12 months.
2 Antidepressant change.
3 Association to another antidepressant.
4 Increase in antidepressant dose.
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information, misguided ideas about mental diseases, lack
of family support, cognitive impairment, adverse reac-
tions and side effects, and/or deficient physician-patient
communication. Treatment should undoubtedly in-
clude, in addition to pharmacologic treatment, indivi-
dualized interventions with educational and behavioral
components [35].
The referral rate to mental health care was 18.8%,
mainly due to inadequate response to treatment and dis-
ease severity. Kendrick et al. reported an overall 22.8%
rate of referrals to a psychologist or psychiatrist, as com-
pared to the 25% and 38% rates reported by Wang and
Grembowski, respectively [37-39]. These differences are
probably the result of the different factors involved(training of professionals, psychiatric comorbidities,
organizational models, resources availability) [40,41].
The most commonly used active ingredients were par-
oxetine, fluoxetine, sertraline, and citalopram, all of
them belonging to the selective serotonin reuptake inhi-
bitors class. These are the antidepressants recommended
as first-line treatment in current international guidelines
[8,10,14,15].
The different morbidity burdens found in the two
groups may have an impact on total costs of the disease.
Beyond methodological differences, the results were
similar to those of other reviewed studies, although
other European investigators have also confirmed their
impact by measuring quality of life in these patients
[3,5,42,43]. In our study, direct and indirect costs
Figure 2 Survival curves of time elapsed to psychiatric referral
(B) according to antidepressant response.
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This distribution is similar to that reported in PC popu-
lations in Sweden and Spain, where indirect costs
reached 65% of total costs [5,44].
Data related to the different treatment approaches
used after an inadequate response to first-line anti-
depressant treatment, especially in a primary care set-
ting, is one of the strengths of this study. One aspect of
these results related to the attitude of GPs which dis-
agree with recommendations in clinical practice guide-
lines should be stressed: a significant number of patientsTable 4 Relationship between compliance, persistence, and re
Groups Inadequate response
Number of patients, % N=965 (42.7%)
Treatment compliance
At 6 months 66.2%
At 12 months 65.1%
Treatment persistence
At 6 months 46.5%
At 12 months 31.8%
Referrals to psychiatry
Mean referrals (per patient) 0.2 (0.4)
At 6 months (N = 293) 4.8%
At 12 months (N= 413) 21.6%
Time to referral, months 6.4 (4.0)
Reasons for referral
Disease severity (N = 174) 41.2%
No response to treatment (N= 196) 53.8%
Patient decision (N= 43) 5.0%
Values given as mean (standard deviation). Treatment compliance: ratio between th
discontinuation of initial treatment or without switch to another medication, at leascontinued on the same treatment despite not achieving
remission. A recent publication by Chang et al. (2012)
also found little active management among depressed
patients treated in primary care centers in USA [45].
GPs were not more likely to adjust therapy, even when
feedback regarding their patients´ symptoms indicated
an inadequate response. The STAR-D study showed that
patients with longer depressive episodes were less likely
to achieve remission [46]. After two treatment steps, it
appears that over 50% of patients will achieve remission
if they stay in treatment (i.e.,36.8% step 1 plus 30.6% of
the remaining 63.2% of patients). Thereafter, the chances
of subsequent remission are much lower [46]. Guidelines
of scientific associations for the treatment of patients
with MDD recommend that, when remission is not
achieved with an AD after 6 to 8 weeks of treatment at
adequate dose, this should be changed [10]. However,
controversy remains and there are no conclusive data as
to which is the best alternative available [19,47,48].
The article has several limitations inherent to studies
based on population databases, such as disease underre-
porting or potential variability of professionals in routine
use of the different clinical screening scales [49,50]. In
addition, the most severe cases were possibly not
included in the study because they are usually seen at
mental health centers. Potential bias may have resulted
from the fact that no consideration was given to the
presence or absence of psychotherapeutic interventions
in the course of disease. The only direct costs considered
were those relating to the public health system and the
area of influence of the patient. Sick leaves may in turnferrals to mental health care. Annual follow-up






0.1 (0.4) 0.2 (0.4) 0.005
8.2% 13.1% <0.001
16.8% 18.8% <0.001




e numbers of tablets dispensed/prescribed. Persistence: median time without
t 8 weeks after initial prescription.
Table 5 Use of resources and total cost
Groups Inadequate response Remission Total P value
Number of patients, % N=965 (42.7%) N=1,295 (57.3%) N=2,260 (100%)
Use of resources
Medical visits 16.8 (9.1) 11.1 (8.2) 13.6 (8.9) <0.001
Laboratory tests: 0.6 (0.8) 0.5 (0.7) 0.5 (0.8) <0.001
Supplemental tests 0.1 (0.4) 0.1 (0.3) 0.1 (0.3) NS
Referrals 0.2 (0.4) 0.1 (0.4) 0.2 (0.4) 0.005
Work productivity losses (days) 20.2 (63.7) 12.8 (45.5) 16.1 (54.2) 0.001
Uncorrected cost model (Euros)
- Healthcare costs 857.2 443.2 620.0 <0.001
Medical visits 383.9 253.7 309.3 <0.001
Laboratory tests: 15.0 10.3 12.3 <0.001
Supplemental tests 4.3 2.2 3.1 <0.001
Drugs 453.9 177.1 295.3 <0.001
- Non-healthcare costs (productivity) 1,615.3 1,021.5 1,275.1 0.001
Total cost 2,472.5 1,464.8 1,895.0 <0.001
Corrected cost model (Euros)* Difference
Healthcare costs 826.1 451.2 374.85 <0.001
95% CI 798.5 - 853.5 428.8 - 473.6
Non-healthcare costs (productivity) 1,842.0 991.4 850.64 <0.001
95% CI 1,525.7 - 2,158.3 733.6 - 1249.1
Total cost 2,668.1 1,442.6 1,225.49 <0.001
95% CI 2,346.9 - 2,989.2 1,180.9 - 1,704.2
Values are given as mean (standard deviation); p: statistical significance; CI: confidence interval; Referrals were not considered in the calculation of health costs.
(*) ANCOVA model: each F test contrasts the simple effect of the presence of remission on each combination of levels of the other effects shown. These tests are
based on pairwise, linearly independent comparisons between the estimated marginal means. Random components: remission status and sex; covariates:
comorbidity and age.
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estimates self-employment, and does not take unpaid
work into account.Conclusions
Our findings demonstrate that the therapeutic strategy
most commonly used by GPs for the management of
patients with MDD and an inadequate response to first-
line treatment is switching to a different antidepressant
drug. In addition, there was a significant delay in change
of strategy.
Nowadays, symptomatic remission is the main goal in
the management of major depressive disorder. There-
fore, clinicians should carefully reevaluate patients pre-
senting partial response to AD treatment and to adopt a
faster change of pharmacological strategy.Competing interests
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